A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton?s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Nurix Therapeutics, Inc.
Start Date
January 29, 2024
End Date
January 14, 2029
Administered By
Duke Cancer Institute
Awarded By
Nurix Therapeutics, Inc.
Start Date
January 29, 2024
End Date
January 14, 2029